Quoting sources close to the matter, Bloomberg News reported last week that Bausch Health was currently exploring the possibility of a sale of its Bausch+Lomb’s eye care business unit, instead of the initially planned spin-off. Before being renamed as Bausch Health, Valeant Pharmaceuticals International had acquired Bausch & Lomb Holdings in 2013 for $8.7 billion. According to Bloomberg financial analysts, the eye care business’ current price tag could reach between $20 billion and $30 billion. Bausch Health is believed to be under pressure from the activist investor fund Carl Icahn, which has two of its representatives sitting at the pharmaceutical group’s board of directors since March.